International Journal of Sexually Transmitted Diseases
Call for papers
The International Journal of Sexually Transmitted Diseases welcomes submissions throughout the year across the biology, diagnosis, treatment, epidemiology, prevention and control of sexually transmitted infections.
Primary: ManuscriptZone · Alternative: submission form · Assisted: [email protected]
Open to Regular submissions, year-round Formats Four main groups, plus scholarly correspondence Review Single-blind by default; double-blind review is available on request. Access Open access, CC BY 4.0
01 · The invitation
Submit your research to IJSTD
International Journal of Sexually Transmitted Diseases welcomes submissions throughout the year from researchers, clinicians, and multidisciplinary teams working across sexually transmitted infection — the organisms themselves, the assays that detect them, the care of the people who have them, and the surveillance and prevention that reduce the next infection.
Regular submissions are accepted throughout the year.
The journal is scoped to the infection rather than to a method or a discipline, which is the reason to send work here: a resistance mechanism, an assay evaluation, a treatment trial, a surveillance series and a screening-program evaluation on the same pathogen are read by the same audience in one place, rather than dispersed across five literatures that rarely meet.
02 · What we are reading
Research the journal is inviting
These are the journal's four priority domains, in its own terms. Work that sits between two of them is welcome, and the aims and scope page states each with a worked example of the kind of manuscript that fits it.
-
01
Pathogen biology and molecular mechanisms
Viral pathogenesis in HPV, HSV and sexually transmissible hepatitis; HIV mechanisms relevant to sexual transmission, prevention or STI interactions; bacterial virulence in Neisseria gonorrhoeae, Treponema pallidum and Chlamydia trachomatis; host-pathogen interaction and immune evasion; antimicrobial resistance mechanisms; genomic epidemiology and strain evolution; molecular diagnostics and biomarker discovery.
-
02
Clinical management and therapeutics
Randomized controlled trials of treatment regimens; comparative effectiveness of antimicrobial therapies; management of drug-resistant infection; treatment of co-infections and complications including pelvic inflammatory disease and epididymitis; point-of-care treatment strategies; adverse-event monitoring and pharmacovigilance.
-
03
Epidemiology and public health surveillance
Incidence and prevalence in defined populations; transmission dynamics and network analysis; surveillance system evaluation and enhancement; geographic and temporal trend analysis; risk factor identification and stratification; health disparities in STI burden.
-
04
Prevention and vaccine development
Vaccine immunogenicity and efficacy trials including HPV and hepatitis B; pre-exposure and post-exposure prophylaxis; behavioral intervention effectiveness; screening program evaluation and optimization; partner notification and contact tracing; prophylactic technologies including microbicides and barrier methods.
A substantive contribution to STI transmission, diagnosis, prevention, treatment, care or service access establishes fit. Rigorous behavioral, qualitative, implementation and methodological research may fit without a biological or patient-outcome measurement. HIV research fits where its central question concerns sexual transmission, prevention, interactions with other STIs or sexual-health care; another STI need not be present. Congenital and perinatal transmission remain within the remit.
03 · What to send
Article types and length
Four main manuscript groups cover original research, reviews (including systematic reviews and meta-analyses), case reports or case series, and brief communications or technical notes. Editorials, commentaries and letters are additional scholarly contributions handled with the editorial office. APC categories distinguish these formats without changing their scope. Word counts exclude the abstract, references, tables and figure legends, and the instructions for authors page states abstract structure, reference format, figure requirements and the checklist for each.
| Article type | Length |
|---|---|
| Original research | 4,000–8,000 words |
| Review | 6,000–10,000 words |
| Systematic review and meta-analysis | 6,000–10,000 words |
| Case report or case series | 1,500–3,000 words |
| Brief communication or technical note | 1,000–2,000 words |
| Editorial or commentary | Agreed with the editorial office |
| Letter to the editor | Agreed with the editorial office |
04 · Terms
What a submitting author can expect
- Screening
- All submissions undergo initial editorial screening. Manuscripts that meet the journal's scope and minimum requirements proceed to independent peer review.
- Peer review
- Single-blind by default; double-blind review is available on request. Manuscripts that proceed to external peer review are normally evaluated by at least two independent subject-matter experts.
- Decision criteria
- Editorial decisions are based on scope, scientific quality, methodological rigor, ethical compliance, reporting quality, and relevance to the journal.
- Editorial independence
- Editorial decisions are independent of any fee, service, membership or role.
- Open access and copyright
- Every article is published open access under the Creative Commons Attribution 4.0 license, and copyright is retained by the authors.
- Charges
- There is no submission fee and no reader charge. An article processing charge falls due only after acceptance and is set by article type; the charges page holds the full terms.
05 · Before you write
If you are not sure it fits
Send the title and abstract to [email protected] and the editorial office will read them and say whether it is worth preparing a full submission. That is quicker for both sides than a desk rejection, and it is the same route to use for a proposal for a Special Issue — see Special Issues.
General infectious-disease, immunology or non-infectious sexual-health research without a substantive STI contribution is outside scope. Qualitative and social research is assessed for its STI-related contribution and appropriate methods, not by a universal biological-endpoint requirement.
06 · Routes
How to submit
Three routes reach one editorial office. Authors must use only one submission route for the same manuscript.
-
Primary route — ManuscriptZone
-
Alternative route — simple manuscript submission form
https://openaccesspub.org/manuscript-submission-form?journal=ijstd
-
Assisted route — the editorial office
07 · Routes
Where to go next
- Aims and scopeEvery research domain with a worked example, and the boundary.
- Instructions for authorsLength, structure, references and the checklist.
- Special issuesPropose a focused collection, and the safeguards that govern one.
- Current issueThe most recent research the journal has published.
- Editorial boardWho provides scholarly oversight, and their recorded expertise.
- Article processing chargesCharged after acceptance only, and set by article type.
International Journal of Sexually Transmitted Diseases (IJSTD) · ISSN 2994-6743 · Crossref DOI prefix 10.14302 · published open access by Open Access Pub under CC BY 4.0. Editorial decisions are independent of any fee, service, membership or role.